Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report) insider Vanessa Carle sold 2,567 shares of the firm’s stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $4.00, for a total transaction of $10,268.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Lexaria Bioscience Trading Down 2.7 %
LEXX opened at $3.98 on Friday. The business’s 50-day moving average is $3.11 and its two-hundred day moving average is $2.90. Lexaria Bioscience Corp. has a 1 year low of $0.80 and a 1 year high of $6.85.
Institutional Trading of Lexaria Bioscience
An institutional investor recently bought a new position in Lexaria Bioscience stock. Cowen AND Company LLC bought a new stake in Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 256,327 shares of the company’s stock, valued at approximately $320,000. Cowen AND Company LLC owned about 2.46% of Lexaria Bioscience as of its most recent SEC filing. 13.06% of the stock is owned by institutional investors.
Analyst Ratings Changes
Check Out Our Latest Report on Lexaria Bioscience
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
Further Reading
- Five stocks we like better than Lexaria Bioscience
- Dividend Capture Strategy: What You Need to Know
- Defense Stocks Soar to New Highs; Higher Highs Are Coming
- What Are Trending Stocks? Trending Stocks Explained
- Generac Raises Guidance: Why Is the Stock Still a Hold?
- The How and Why of Investing in Gold Stocks
- Iconic Burger Chain’s Stock Rallies, Defying Market Trends
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.